Is Fortress Biotech, Inc. overvalued or undervalued?

As of 10 May 2016, the valuation grade for Fortress Biotech, Inc. moved from does not qualify to risky. The company is considered overvalued given its negative financial metrics and poor performance compared to peers. The Price to Book Value stands at 2.66, while the EV to EBITDA is -0.31, indicating significant valuation challenges. Additionally, the company's Return on Equity (ROE) is an alarming -482.55%, further underscoring its financial instability.
In comparison to peers, Fortress Biotech's EV to EBITDA ratio is better than Assembly Biosciences, Inc. at -6.6467 and Sol-Gel Technologies Ltd. at -11.1084, but still reflects a concerning trend. The stock has shown a strong return of 85.42% over the past year, significantly outperforming the S&P 500's 17.14% return, although its longer-term performance remains troubling with a 5-year return of -95.03%.